Novartis Prexige NDA Has Data Vs. COX-2s; Forest Filing Lexapro Extensions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis’ NDA for its COX-2 inhibitor Prexige, contains clinical studies in osteoarthritis, rheumatoid arthritis, acute pain (including postoperative and dental) and primary dysmenorrhea.